Description

Finding and applying synergies among industry, academia, patients and non-profit foundations can significantly minimize the risk of failure and increase the probability of success in drug discovery and development. In this session, panelists will discuss key elements of successful collaborations, including (1) optimizing contractual terms to align with the goals of each party, (2) positioning participants and stakeholders to leverage their respective skills and experiences, (3) designing and implementing an appropriate R&D plan, (4) inserting a governance structure to facilitate R&D, and (5) measuring and communicating outcomes so that efforts can be redirected when necessary. The principles of synergistic collaboration are scalable and can be applied to guide drug discovery and development for rare diseases, as well as larger therapeutic indications.


Learning Objectives:

  • Detail the types of partnerships and the strengths and weaknesses inherent in these arrangements
  • Examine successful examples of how to leverage partner's strengths and bolster weaknesses
  • Identify key traits desirable in partners and strategies for initiating and building the right relationships

Ability Level: Intermediate

Session ID: 1968

myBIO Chatter

Speakers (2)

User Tom Daniel President of Research and Early Development Celgene
User Tadataka Yamada Chief Medical & Scientific Officer Takeda Pharmaceuticals International

Moderators (1)

contact_4655 John Mendlein, Ph.D. Executive Chairman and CEO aTyr Pharma, Inc.